Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study

The Lancet Oncology

Volumn 18, Issue 1, 2017, Pages 88-99

  Passamonti, Francesco ^a   Griesshammer, Martin ^b   Palandri, Francesca ^c   Egyed, Miklos ^d   Benevolo, Giulia ^e   Devos, Timothy ^f   Callum, Jeannie ^g   Vannucchi, Alessandro M ^h   Sivgin, Serdar ⁱ   Bensasson, Caroline ^j   Khan, Mahmudul ^j   Mounedji, Nadjat ^k   Saydam, Guray ^l  

^a UNIVERSITY OF INSUBRIA   (Italy)

^b KLINIKUM MINDEN   (Germany)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d Kaposi Mor Teaching Hospital   (Hungary)

^e CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^g SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^h UNIVERSITY OF FLORENCE   (Italy)

ⁱ ERCIYES UNIVERSITY   (Turkey)

^j NOVARTIS PHARMA AG   (Switzerland)

^k NOVARTIS PHARMA K K   (Japan)

^l EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA GLUTAMYLTRANSFERASE; HYDROXYUREA; INTERFERON; LACTATE DEHYDROGENASE; LENALIDOMIDE; PEGINTERFERON; PIPOBROMAN; RUXOLITINIB; TRIACYLGLYCEROL LIPASE; URIC ACID; PYRAZOLE DERIVATIVE;

ABDOMINAL PAIN; ACTINIC KERATOSIS; ADULT; AGED; ANEMIA; ANGINA PECTORIS; APHTHOUS STOMATITIS; ARTHRALGIA; ARTICLE; ASTHENIA; ATRIAL FIBRILLATION; BACKACHE; BACTERIAL PNEUMONIA; BLADDER CANCER; BLEEDING; BREAST CANCER; BRONCHITIS; CELLULITIS; CONSTIPATION; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; CYSTITIS; DEATH; DEHYDRATION; DIARRHEA; DIGESTIVE SYSTEM INFLAMMATION; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ERYTHEMA; ERYTHROMELALGIA; FAINTNESS; FATIGUE; FEMALE; FEVER; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HEART FAILURE; HEMATOCRIT; HEMATOMA; HERPES ZOSTER; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPESTHESIA; HYPONATREMIA; INFLUENZA; KIDNEY FAILURE; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTOSIS; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MELANOMA; MOOD DISORDER; MOUTH ULCER; MULTICENTER STUDY; NEUTROPENIA; NIGHT SWEAT; OPEN STUDY; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PHLEBITIS; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PRURITUS; PULMONARY ASPIRATION; RANDOMIZED CONTROLLED TRIAL; REMISSION; RESPIRATORY FAILURE; RHINOPHARYNGITIS; SEPTIC SHOCK; SIDE EFFECT; SPLENOMEGALY; SQUAMOUS CELL CARCINOMA; SUICIDAL IDEATION; THROMBOCYTOPENIA; THROMBOCYTOSIS; TINNITUS; UPPER RESPIRATORY TRACT INFECTION; URIC ACID BLOOD LEVEL; UROSEPSIS; VOMITING; WEIGHT GAIN; CANCER STAGING; CLINICAL TRIAL; DRUG EFFECTS; DRUG RESISTANCE; FOLLOW UP; GENETICS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; SALVAGE THERAPY; SURVIVAL RATE; TUMOR RECURRENCE;

AGED; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POLYCYTHEMIA VERA; PROGNOSIS; PROSPECTIVE STUDIES; PYRAZOLES; SALVAGE THERAPY; SPLENOMEGALY; SURVIVAL RATE;

EID: 85007494949     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(16)30558-7     Document Type: Article

References (37)

1. 1 Vannucchi, AM, Insights into the pathogenesis and management of thrombosis in polycythemia vera and essential thrombocythemia. Intern Emerg Med 5 (2010), 177–184.
2. 2 Vardiman, JW, Thiele, J, Arber, DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114 (2009), 937–951.
3. 3 Levine, RL, Pardanani, A, Tefferi, A, Gilliland, DG, Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 7 (2007), 673–683.
4. 4 Tefferi, A, Rumi, E, Finazzi, G, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia 27 (2013), 1874–1881.
5. 5 Reiter, A, Harrison, C, How we identify and manage patients with inadequately controlled polycythemia vera. Curr Hematol Malig Rep 11 (2016), 356–367.
6. 6 Passamonti, F, Rumi, E, Pungolino, E, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 117 (2004), 755–761.
7. 7 Passamonti, F, Rumi, E, Caramella, M, et al. A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis. Blood 111 (2008), 3383–3387.
8. 8 Marchioli, R, Finazzi, G, Landolfi, R, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 23 (2005), 2224–2232.
9. 9 Geyer, H, Scherber, R, Kosiorek, H, et al. Symptomatic profiles of patients with polycythemia vera: implications of inadequately controlled disease. J Clin Oncol 34 (2016), 151–159.
10. 10 Barbui, T, Barosi, G, Birgegard, G, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 29 (2011), 761–770.
11. 11 Marchioli, R, Finazzi, G, Specchia, G, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med 368 (2013), 22–33.
12. 12 Barbui, T, Masciulli, A, Marfisi, MR, et al. White blood cell counts and thrombosis in polycythemia vera: a subanalysis of the CYTO-PV study. Blood 126 (2015), 560–561.
13. 13 Vannucchi, AM, Kiladjian, JJ, Griesshammer, M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med 372 (2015), 426–435.
14. 14 Alvarez-Larrán, A, Pereira, A, Cervantes, F, et al. Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera. Blood 119 (2012), 1363–1369.
15. 15 Alvarez-Larrán, A, Kerguelen, A, Hernández-Boluda, JC, et al. Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera. Br J Haematol 172 (2016), 786–793.
16. 16 Randi, ML, Ruzzon, E, Luzzatto, G, Tezza, F, Girolami, A, Fabris, F, Safety profile of hydroxyurea in the treatment of patients with Philadelphia-negative chronic myeloproliferative disorders. Haematologica 90 (2005), 261–262.
17. 17 European Medicines Agency. Summary of opinion (post authorisation) for Jakavi (ruxolitinib). http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion/human/002464/WC500180876.pdf (accessed Nov 16, 2016).
18. 18 FDA. FDA approved ruxolitinib. http://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm425732.htm (accessed Nov 16, 2016).
19. 19 Vannucchi, AM, Verstovsek, S, Jones, MM, et al. Efficacy of ruxolitinib by baseline spleen volume in patients with polycythemia vera resistant to or intolerant of hydroxyurea. Blood, 124, 2014, 1840 (abstract).
20. 20 Vannucchi, AM, Antonioli, E, Guglielmelli, P, et al. Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia 21 (2007), 1952–1959.
21. 21 Abdulkarim, K, Ridell, B, Johansson, P, Kutti, J, Safai-Kutti, S, Andreasson, B, The impact of peripheral blood values and bone marrow findings on prognosis for patients with essential thrombocythemia and polycythemia vera. Eur J Haematol 86 (2011), 148–155.
22. 22 Barosi, G, Birgegard, G, Finazzi, G, et al. A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. Br J Haematol 148 (2010), 961–963.
23. 23 Finazzi, G, Caruso, V, Marchioli, R, et al. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood 105 (2005), 2664–2670.
24. 24 Crisa, E, Venturino, E, Passera, R, et al. A retrospective study on 226 polycythemia vera patients: impact of median hematocrit value on clinical outcomes and survival improvement with anti-thrombotic prophylaxis and non-alkylating drugs. Ann Hematol 89 (2010), 691–699.
25. 25 Verstovsek, S, Mesa, RA, Gotlib, J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366 (2012), 799–807.
26. 26 Harrison, C, Kiladjian, JJ, Al-Ali, HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366 (2012), 787–798.
27. 27 Verstovsek, S, Vannucchi, AM, Griesshammer, M, et al. Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial. Haematologica 101 (2016), 821–829.
28. 28 Kaifie, A, Kirschner, M, Wolf, D, et al. Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry. J Hematol Oncol, 9, 2016, 18.
29. 29 Kiladjian, JJ, Cassinat, B, Chevret, S, et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 112 (2008), 3065–3072.
30. 30 Quintás-Cardama, A, Abdel-Wahab, O, Manshouri, T, et al. Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon alpha-2a. Blood 122 (2013), 893–901.
31. 31 Gisslinger, H, Zagrijtschuk, O, Buxhofer-Ausch, V, et al. Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera. Blood 126 (2015), 1762–1769.
32. 32 Hasselbalch, HC, Bjørn, ME, Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med, 372, 2015, 1670.
33. 33 Kiladjian, J, Guglielmelli, P, Griesshammer, M, et al. Ruxolitinib treatment following interferon in patients with polycythemia vera: An analysis from the RESPONSE trial. Haematologica, 101(suppl 2), 2016, E1360 (abstract).
34. 34 Ahn, IE, Natelson, E, Rice, L, Successful long-term treatment of Philadelphia chromosome-negative myeloproliferative neoplasms with combination of hydroxyurea and anagrelide. Clin Lymphoma Myeloma Leuk 13:suppl 2 (2013), S300–S304.
35. 35 Alvarez-Larrán, A, Martínez-Avilés, L, Hernández-Boluda, JC, et al. Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea. Ann Hematol 93 (2014), 2037–2043.
36. 36 Verstovsek, S, Passamonti, F, Rambaldi, A, et al. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer 120 (2014), 513–520.
37. 37 Antonioli, E, Guglielmelli, P, Pieri, L, et al. Hydroxyurea-related toxicity in 3411 patients with Ph'-negative MPN. Am J Hematol 87 (2012), 552–554.